Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study

Konsta Teppo, Jussi Jaakkola, K E Juhani Airaksinen, Fausto Biancari, Olli Halminen, Jukka Putaala, Pirjo Mustonen, Jari Haukka, Juha Hartikainen, Alex Luojus, Mikko Niemi, Miika Linna, Mika Lehto, Konsta Teppo, Jussi Jaakkola, K E Juhani Airaksinen, Fausto Biancari, Olli Halminen, Jukka Putaala, Pirjo Mustonen, Jari Haukka, Juha Hartikainen, Alex Luojus, Mikko Niemi, Miika Linna, Mika Lehto

Abstract

Background Mental health conditions (MHCs) are associated with poor outcomes in patients with atrial fibrillation. However, persistence of oral anticoagulation therapy in patients with atrial fibrillation and MHCs is unknown. We aimed to evaluate the effect of MHCs on the persistence of direct oral anticoagulant (DOAC) use in patients with atrial fibrillation based on a nationwide cohort. Methods and Results The nationwide registry-based FinACAF (Finnish Anticoagulation in Atrial Fibrillation) cohort included 67 503 patients with incident atrial fibrillation and indication for permanent oral anticoagulation (CHA2DS2-VASc score >1 in men and >2 in women) starting DOAC therapy between 2011 and 2018. MHCs of interest were depression, bipolar disorder, anxiety disorder, schizophrenia, and composite of any MHC. The main outcome was nonpersistence of DOAC use, defined as the first 120-day period without DOAC purchases after drug initiation. The mean age of the patients was 75.3±8.9 years, 53.6% were women, and the prevalence of any MHC was 17.8%. Persistence after 1 year from DOAC initiation was 79.3% in patients without MHCs and 77.2% in patients with any MHC, and after 2 years were 64.4% and 60.6%, respectively (P<0.001). Higher incidence of nonpersistence to DOACs was observed in all MHC categories: adjusted subdistribution hazard ratios, 1.16 (95% CI, 1.11-1.21) for any MHC, 1.32 (95% CI, 1.22-1.42) for depression, 1.44 (95% CI, 1.15-1.80) for bipolar disorder, 1.25 (95% CI, 1.11-1.41) for anxiety disorder, and 1.30 (95% CI, 1.02-1.64) for schizophrenia. However, patients with only anxiety disorder without other MHCs were not at higher risk of nonpersistence. Conclusions MHCs are associated with nonpersistence of DOAC use. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04645537.

Keywords: atrial fibrillation; depression; direct oral anticoagulants; mental health conditions; persistence.

Figures

Figure 1. Cumulative incidence function of direct…
Figure 1. Cumulative incidence function of direct oral anticoagulant therapy nonpersistence in patients with and without any mental health condition (MHC).
Figure 2. Cumulative incidence function of direct…
Figure 2. Cumulative incidence function of direct oral anticoagulant therapy nonpersistence in patients with depression, bipolar disorder, anxiety disorder, or schizophrenia vs patients without a mental health condition (MHC).

References

    1. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population‐based study. Stroke. 2013;44:3103–3108. doi: 10.1161/STROKEAHA.113.002329
    1. Wang L, Ze F, Li J, Mi L, Han B, Niu H, Zhao N. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. Heart. 2021;107:881–887. doi: 10.1136/heartjnl-2020-317656
    1. Hart RG, Pearce LA, Aguilar MI. Meta‐analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857. doi: 10.7326/0003-4819-146-12-200706190-00007
    1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta‐analysis of randomised trials. The Lancet. 2014;383:955–962. doi: 10.1016/S0140-6736(13)62343-0
    1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström‐Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, ESC Scientific Document Group , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373‐498. doi: 10.1093/eurheartj/ehaa612
    1. Fenger‐Grøn M, Vestergaard CH, Frost L, Davydow DS, Parner ET, Christensen B, Ribe AR. Depression and uptake of oral anticoagulation therapy in patients with atrial fibrillation: a Danish nationwide cohort study. Med Care. 2020;58:216–224. doi: 10.1097/MLR.0000000000001268
    1. Fenger‐Grøn M, Vestergaard CH, Ribe AR, Johnsen SP, Frost L, Sandbæk A, Davydow DS. Association between bipolar disorder or schizophrenia and oral anticoagulation use in Danish adults with incident or prevalent atrial fibrillation. JAMA Network Open. 2021;4:e2110096. doi: 10.1001/jamanetworkopen.2021.10096
    1. Søgaard M, Skjøth F, Kjældgaard JN, Larsen TB, Hjortshøj SP, Riahi S. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open. 2017;7. doi: 10.1136/bmjopen-2017-018209
    1. Teppo K, Jaakkola J, Lehto M, Biancari F, Airaksinen KEJ. The impact of mental health conditions on oral anticoagulation therapy and outcomes in patients with atrial fibrillation: a systematic review and meta‐analysis. Am J Prev Cardiol. 2021;7:100221. doi: 10.1016/j.ajpc.2021.100221
    1. Komen JJ, Heerdink ER, Klungel OH, Mantel‐Teeuwisse AK, Forslund T, Wettermark B, Hjemdahl P. Long‐term persistence and adherence with non‐vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J–Cardiovasc Pharmacother. 2021;7:f72–f80. doi: 10.1093/ehjcvp/pvaa017
    1. Holvast F, Wouters H, Hek K, Schellevis F, Oude Voshaar R, van Dijk L, Burger H, Verhaak P. Non‐adherence to cardiovascular drugs in older patients with depression: a population‐based cohort study. Int J Cardiol. 2019;274. doi: 10.1016/j.ijcard.2018.08.100
    1. Springer SA, Dushaj A, Azar MM. The impact of DSM‐IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16. doi: 10.1007/s10461-012-0212-3
    1. Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid‐enrolled patients with schizophrenia. J Pharm Health Serv Res. 2013;4:29–39. doi: 10.1111/jphs.12004
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H‐C, Heidbuchel H, Hendriks J, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;2016:37. doi: 10.5603/KP.2016.0172
    1. John Camm A, Lip GYH, de Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33. doi: 10.1016/j.rec.2012.11.003
    1. GBD 2019 Mental Disorders Collaborators . Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990‐2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–150. doi: 10.1016/S2215-0366(21)00395-3
    1. Lowres N, Giskes K, Hespe C, Freedman B. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ J. 2019;49:883. doi: 10.4070/kcj.2019.0234
    1. Rodriguez‐Bernal CL, Peiró S, Hurtado I, García‐Sempere A, Sanfélix‐Gimeno G. Primary nonadherence to oral anticoagulants in patients with atrial fibrillation: real‐world data from a population‐based cohort. J Manag Care Spec Pharm. 2018;24. doi: 10.18553/jmcp.2018.24.5.440
    1. Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ, Strain WD, Ryan R, Watkins C, Marshall T, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population‐based study. Heart. 2020;106:119–126. doi: 10.1136/heartjnl-2019-315307
    1. Stoehr GP, Lu S‐Y, Lavery L, Bilt JV, Saxton JA, Chang C‐C, Ganguli M. Factors associated with adherence to medication regimens in older primary care patients: the steel valley seniors survey. Am J Geriatr Pharmacother. 2008;6:255–263. doi: 10.1016/j.amjopharm.2008.11.001
    1. Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J. Adherence, persistence, and medication discontinuation in patients with attention‐deficit/hyperactivity disorder—a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569. doi: 10.2147/NDT.S65721
    1. Komen JJ, Pottegård A, Mantel‐Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hellfritzsch M, Hallas J, Olesen M, Bennie M, et al. Persistence and adherence to non‐vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. EP Europace. 2021;23:1722–1730. doi: 10.1093/europace/euab091
    1. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther. 2005;22:313–356. doi: 10.1007/BF02850081.
    1. Fioravanti M, Carlone O, Vitale B, Cinti ME, Clare L. A meta‐analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev. 2005;15. doi: 10.1007/s11065-005-6254-9
    1. Gillis JC, Chang SC, Devore EE, Rosner BA, Grodstein F, Okereke OI. Patterns of late‐life depressive symptoms and subsequent declines in cognitive domains. Int J Geriatr Psychiatry. 2017;32. doi: 10.1002/gps.4618
    1. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan‐Schilling V, Rowell N, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23:1612–1676. doi: 10.1093/europace/euab065
    1. Wikström K, Toivakka M, Rautiainen P, Tirkkonen H, Repo T, Laatikainen T. Electronic health records as valuable data sources in the health care quality improvement process. Health Serv Res Manag Epidemiol. 2019;6. doi: 10.1177/2333392819852879
    1. Rapola JM, Virtamo J, Korhonen P, Haapakoski J, Hartman AM, Edwards BK, Heinonen OP. Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland. Eur J Epidemiol. 1997;13:133–138. doi: 10.1023/a:1007380408729
    1. Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40:505–515. doi: 10.1177/1403494812456637
    1. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705. doi: 10.1111/j.1365-2125.2012.04167.x

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner